• 29024 Citations
  • 70 h-Index
1977 …2019
If you made any changes in Pure these will be visible here soon.

Research Output 1977 2019

  • 29024 Citations
  • 70 h-Index
  • 242 Article
  • 5 Chapter
  • 1 Book
  • 1 Review article
2019
4 Citations (Scopus)

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: Long-term follow-up of the BiG 1-98 trial

BIG 1-98 Collaborative Group and the International Breast Cancer Study Group, Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 105-114 10 p.

Research output: Contribution to journalArticle

letrozole
Tamoxifen
Hormones
Breast Neoplasms
Disease-Free Survival

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 31 others, La Verde, N., Bianchi, G. V., Artale, S., Blasi, L., De Laurentiis, M., Atzori, F., Turletti, A., Porpiglia, M., Santini, D., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Giordano, M., Donadio, M., Biganzoli, L., Del Mastro, L., Bisagni, G., Livi, L., Natoli, C., Montemurro, F., Riccardi, F., Romagnoli, E., Marchetti, P., Torri, V., Pronzato, P. & Mustacchi, G., Jan 1 2019, In : Breast Care.

Research output: Contribution to journalArticle

Extravehicular Activity
Breast Neoplasms
Therapeutics
Aromatase Inhibitors
Datasets
2018

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Gagno, S., D'Andrea, M. R., Mansutti, M., Zanusso, C., Puglisi, F., Dreussi, E., Montico, M., Biason, P., Cecchin, E., Iacono, D., Russo, S., Cinausero, M., Saracchini, S., Gasparini, G., Sartori, D., Bari, M., Collovà, E., Meo, R., Merkabaoui, G., Spagnoletti, I. & 20 others, Pellegrino, A., Gianni, L., Sandri, P., Cretella, E., Vattemi, E., Rocca, A., Serra, P., Fabbri, M. A., Benedetti, G., Foghini, L., Medici, M., Basso, U., Amoroso, V., Riccardi, F., Baldelli, A. M., Clerico, M., Bonura, S., Saggia, C., Innocenti, F. & Toffoli, G., Jan 1 2018, In : Clinical Breast Cancer.

Research output: Contribution to journalArticle

exemestane
Prospective Studies
Breast Neoplasms
Biomarkers
Population

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Gagno, S., D'Andrea, M. R., Mansutti, M., Zanusso, C., Puglisi, F., Dreussi, E., Montico, M., Biason, P., Cecchin, E., Iacono, D., Russo, S., Cinausero, M., Saracchini, S., Gasparini, G., Sartori, D., Bari, M., Collovà, E., Meo, R., Merkabaoui, G., Spagnoletti, I. & 20 others, Pellegrino, A., Gianni, L., Sandri, P., Cretella, E., Vattemi, E., Rocca, A., Serra, P., Fabbri, M. A., Benedetti, G., Foghini, L., Medici, M., Basso, U., Amoroso, V., Riccardi, F., Baldelli, A. M., Clerico, M., Bonura, S., Saggia, C., Innocenti, F. & Toffoli, G., Jan 1 2018, (Accepted/In press) In : Clinical Breast Cancer.

Research output: Contribution to journalArticle

exemestane
Prospective Studies
Breast Neoplasms
Biomarkers
Population

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Gagno, S., D'Andrea, M. R., Mansutti, M., Zanusso, C., Puglisi, F., Dreussi, E., Montico, M., Biason, P., Cecchin, E., Iacono, D., Russo, S., Cinausero, M., Saracchini, S., Gasparini, G., Sartori, D., Bari, M., Collovà, E., Meo, R., Merkabaoui, G., Spagnoletti, I. & 20 others, Pellegrino, A., Gianni, L., Sandri, P., Cretella, E., Vattemi, E., Rocca, A., Serra, P., Fabbri, M. A., Benedetti, G., Foghini, L., Medici, M., Basso, U., Amoroso, V., Riccardi, F., Baldelli, A. M., Clerico, M., Bonura, S., Saggia, C., Innocenti, F. & Toffoli, G., 2018, In : Clinical Breast Cancer.

Research output: Contribution to journalArticle

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma

Reni, M., Zanon, S., Balzano, G., Passoni, P., Pircher, C., Chiaravalli, M., Fugazza, C., Ceraulo, D., Nicoletti, R., Arcidiacono, PG., Macchini, M., Peretti, U., Castoldi, R., Doglioni, C., Falconi, M., Partelli, S. & Gianni, L., 2018, In : European Journal of Cancer. 102, p. 95-102 8 p.

Research output: Contribution to journalArticle

gemcitabine
Cisplatin
Adenocarcinoma
Disease-Free Survival
Survival
15 Citations (Scopus)

Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., Chacon, J. I., Chan, A., Morales, S., Alvarez, I., Plazaola, A., Zambetti, M., Redfern, A. D., Dittrich, C., Dent, R. A., Magazzu, D., De Fato, R., Valagussa, P. & 1 others, Tusquets, I., Mar 1 2018, In : JAMA oncology. 4, 3, p. 302-308 7 p.

Research output: Contribution to journalArticle

Phase III Clinical Trials
Neoadjuvant Therapy
Anthracyclines
Paclitaxel
Randomized Controlled Trials

Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., Chacon, JI., Chan, A., Morales, S., Alvarez, I., Plazaola, A., Zambetti, M., Redfern, AD., Dittrich, C., Dent, RA., Magazzu, D., De Fato, R., Valagussa, P. & 1 others, Tusquets, I., 2018, In : JAMA oncology. 4, 3, p. 302-308 7 p.

Research output: Contribution to journalArticle

Phase III Clinical Trials
Neoadjuvant Therapy
Anthracyclines
Paclitaxel
Randomized Controlled Trials

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Blumenthal, GM., Bunn, PA., Chaft, JE., McCoach, CE., Perez, EA., Scagliotti, GV., Carbone, DP., Aerts, HJWL., Aisner, DL., Bergh, J., Berry, DA., Jarkowski, A., Botwood, N., Cross, DAE., Diehn, M., Drezner, NL., Doebele, RC., Blakely, CM., Eberhardt, WEE., Felip, E. & 23 others, Gianni, L., Keller, SP., Leavey, PJ., Malik, S., Pignatti, F., Prowell, TM., Redman, MW., Rizvi, NA., Rosell, R., Rusch, V., de Ruysscher, D., Schwartz, LH., Sridhara, R., Stahel, RA., Swisher, S., Taube, JM., Travis, WD., Keegan, P., Wiens, JR., Wistuba, II., Wynes, MW., Hirsch, FR. & Kris, MG., 2018, In : Journal of Thoracic Oncology. 13, 12, p. 1818-1831 14 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Lung Neoplasms
Oncogenes
Pharmaceutical Preparations
Immunotherapy
2 Citations (Scopus)

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

Petrelli, F., Lazzari, C., Ardito, R., Borgonovo, K., Bulotta, A., Conti, B., Cabiddu, M., Capitanio, J. F., Brighenti, M., Ghilardi, M., Gianni, L., Barni, S. & Gregorc, V., Jul 1 2018, In : PLoS One. 13, 7, e0201425.

Research output: Contribution to journalArticle

systematic review
lung neoplasms
Non-Small Cell Lung Carcinoma
Brain Neoplasms
metastasis

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

Petrelli, F., Lazzari, C., Ardito, R., Borgonovo, K., Bulotta, A., Conti, B., Cabiddu, M., Capitanio, JF., Brighenti, M., Ghilardi, M., Gianni, L., Barni, S. & Gregorc, V., 2018, In : PLoS One. 13, 7, e0201425.

Research output: Contribution to journalArticle

systematic review
lung neoplasms
Non-Small Cell Lung Carcinoma
Brain Neoplasms
metastasis
28 Citations (Scopus)

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

on behalf of the SOLE Investigators, Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 127-138 12 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Disease-Free Survival
Therapeutics

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Nanni, O., Amadori, D., De Censi, A., Rocca, A., Freschi, A., Bologna, A., Gianni, L., Rosetti, F., Amaducci, L., Cavanna, L., Foca, F., Sarti, S., Serra, P., Valmorri, L., Bruzzi, P., Corradengo, D., Gennari, A., Scaltriti, L., Turolla, G. M., Dazzi, C. & 6 others, Cortesi, L., Giovanis, P., Saracchini, S., Ciccarese, M., Carrozza, F. & investigators, MYME., 2018, In : Breast Cancer Research and Treatment.

Research output: Contribution to journalArticle

Metformin
Disease-Free Survival
Clinical Trials
Breast Neoplasms
Drug Therapy
4 Citations (Scopus)
Metformin
Disease-Free Survival
Clinical Trials
Breast Neoplasms
Drug Therapy
37 Citations (Scopus)

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., Feb 1 2018, In : The Lancet Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
palbociclib
fulvestrant
pertuzumab

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., Feb 2018, In : The Lancet. Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
palbociclib
fulvestrant
pertuzumab

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., 2018, In : The Lancet Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
Safety
palbociclib
fulvestrant

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., 2018, In : The Lancet Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
palbociclib
fulvestrant
pertuzumab

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

Pietri, E., Massa, I., Bravaccini, S., Ravaioli, S., Tumedei, M. M., Petracci, E., Donati, C., Schirone, A., Piacentini, F., Gianni, L., Nicolini, M., Campadelli, E., Gennari, A., Saba, A., Campi, B., Valmorri, L., Andreis, D., Fabbri, F., Amadori, D. & Rocca, A., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Dehydroepiandrosterone
Androgen Receptors
Breast Neoplasms
Estrogen Receptors
Aromatase Inhibitors

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study

Zambetti, M., Montemurro, F., Morandi, P., Zamagni, C., Brandes, A. A., Bisagni, G., Cagossi, K., Bengala, C., Gori, S., Iannacone, C., Stell, A. & Gianni, L., Dec 1 2018, In : European Journal of Cancer. 105, p. 61-70 10 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
Safety
Taxoids
Injections

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study

Zambetti, M., Montemurro, F., Morandi, P., Zamagni, C., Brandes, A. A., Bisagni, G., Cagossi, K., Bengala, C., Gori, S., Iannacone, C., Stell, A. & Gianni, L., 2018, In : European Journal of Cancer. 105, p. 61-70 10 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
Safety
Taxoids
Injections

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: Tested doses and rationale for dose selection

Viala, M., Vinches, M., Alexandre, M., Mollevi, C., Durigova, A., Hayaoui, N., Homicsko, K., Cuenant, A., Gongora, C., Gianni, L. & Tosi, D., 2018, In : British Journal of Cancer. 118, 5, p. 679-697 19 p.

Research output: Contribution to journalArticle

Monoclonal Antibodies
MEDLINE
2017
164 Citations (Scopus)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., Baselga, J., Al-Sakaff, N., Lauer, S., McFadden, E., Leyland-Jones, B., Bell, R., Dowsett, M., Jackisch, C. & Herceptin Adjuvant (HERA) Trial Study Team, Mar 25 2017, In : The Lancet. 389, 10075, p. 1195-1205 11 p.

Research output: Contribution to journalArticle

Adjuvant Chemotherapy
Breast Neoplasms
Observation
Disease-Free Survival
Trastuzumab
164 Citations (Scopus)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cameron, D., Piccart-Gebhart, MJ., Gelber, RD., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., Baselga, J., Al-Sakaff, N., Lauer, S., McFadden, E., Leyland-Jones, B., Bell, R., Dowsett, M., Jackisch, C. & Team, F. T. H. A. HERA. T. S., 2017, In : The Lancet. 389, 10075, p. 1195-1205 11 p.

Research output: Contribution to journalArticle

Adjuvant Chemotherapy
Breast Neoplasms
Observation
Disease-Free Survival
Trastuzumab
26 Citations (Scopus)

Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Bianchini, G., Kiermaier, A., Bianchi, G. V., Im, Y. H., Pienkowski, T., Liu, M. C., Tseng, L. M., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, L. C., Valagussa, P. & Gianni, L., Feb 9 2017, In : Breast Cancer Research. 19, 1, 16.

Research output: Contribution to journalArticle

docetaxel
Neoadjuvant Therapy
Biomarkers
Breast Neoplasms
Estrogen Receptors
26 Citations (Scopus)

Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Bianchini, G., Kiermaier, A., Bianchi, GV., Im, YH., Pienkowski, T., Liu, MC., Tseng, LM., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, LC., Valagussa, P. & Gianni, L., 2017, In : Breast Cancer Research. 19, 6, 16.

Research output: Contribution to journalArticle

docetaxel
Neoadjuvant Therapy
Biomarkers
Breast Neoplasms
Estrogen Receptors
8 Citations (Scopus)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial

Earl, HM., Hiller, L., Dunn, JA., Blenkinsop, C., Grybowicz, L., Vallier, AL., Gounaris, I., Abraham, JE., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, JMS., Cameron, DA., Provenzano, E., Thomas, J., Hayward, RL. & 2 others, Group, F. T. ART. I. & Gianni, L., 2017, In : Annals of Oncology. 28, 8, p. 1817-1824 8 p.

Research output: Contribution to journalArticle

docetaxel
Epirubicin
Fluorouracil
Cyclophosphamide
Disease-Free Survival
13 Citations (Scopus)

Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer

Hanker, AB., Estrada, MV., Bianchini, G., Moore, PD., Zhao, J., Cheng, F., Koch, JP., Gianni, L., Tyson, DR., Sanchez, V., Rexer, BN., Sánders, ME., Zhao, Z., Stricker, TP. & Arteaga, CL., 2017, In : Cancer Research. 77, 12, p. 3280-3292 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Integrins
Extracellular Matrix
Collagen
Breast Neoplasms
113 Citations (Scopus)

HER2-positive breast cancer

Loibl, S. & Gianni, L., 2017, In : The Lancet. 389, 1, p. 2415-2429 15 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Neoadjuvant Therapy
Therapeutics
Disease-Free Survival
Survival Rate
14 Citations (Scopus)

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Swain, SM., Schneeweiss, A., Gianni, L., Gao, JJ., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, MS., Yoo, B., Cortes, J. & Baselga, J., 2017, In : Annals of Oncology. 28, 4, p. 761-768 8 p.

Research output: Contribution to journalArticle

Diarrhea
Breast Neoplasms
Incidence
Febrile Neutropenia
Epidermal Growth Factor Receptor
12 Citations (Scopus)

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma

Reni, M., Zanon, S., Balzano, G., Nobile, S., Pircher, CC., Chiaravalli, M., Passoni, P., Arcidiacono, PG., Nicoletti, R., Crippa, SS., Slim, N., Doglioni, C., Falconi, M. & Gianni, L., 2017, In : Annals of oncology : official journal of the European Society for Medical Oncology. 28, 11, p. 2786-2792 7 p.

Research output: Contribution to journalArticle

Adenocarcinoma
Drug Therapy
gemcitabine
Survival
Patient Selection
80 Citations (Scopus)

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, IE., Blackwell, K., Hoersch, S., Xu, J., Green, M. & Gianni, L., 2017, In : The Lancet Oncology. 18, 6, p. 732-742 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Survival
Safety
Survival Analysis
Random Allocation
2016
195 Citations (Scopus)

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G. & Valagussa, P., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V. A., Douthwaite, H., Ross, G. & Valagussa, P., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Gianni, L., Pienkowski, T., Im, Y-H., Tseng, L-M., Liu, M-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S-A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G. & Valagussa, P., Jun 1 2016, In : The Lancet Oncology. 17, 6, p. 791 - 800 10 p.

Research output: Contribution to journalArticle

Breast Neoplasms
docetaxel
Disease-Free Survival
pertuzumab
Trastuzumab

A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

Fiedler, W., Dedosso, S., Cresta, S., Weidmann, J., Tessari, A., Salzberg, M., Dietrich, B., Baumeister, H., Goletz, S., Gianni, L. & Sessa, C., Aug 1 2016, In : European Journal of Cancer. 63, p. 55-63 9 p.

Research output: Contribution to journalArticle

Glycopeptides
Epitopes
Monoclonal Antibodies
Carcinoma
Neoplasms
13 Citations (Scopus)

A phase i study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

Fiedler, W., Dedosso, S., Cresta, S., Weidmann, J., Tessari, A., Salzberg, M., Dietrich, B., Baumeister, H., Goletz, S., Gianni, L. & Sessa, C., Aug 1 2016, In : European Journal of Cancer. 63, p. 55-63 9 p.

Research output: Contribution to journalArticle

Glycopeptides
Epitopes
Monoclonal Antibodies
Carcinoma
Neoplasms

Bevacizumab prevents brain metastases formation in lung adenocarcinoma

Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., Von Baumgarten, L., Preusser, M., Wick, W. & Winkler, F., 2016, In : Molecular Cancer Therapeutics. 15, 4, p. 702-710 9 p.

Research output: Contribution to journalArticle

39 Citations (Scopus)

Bevacizumab prevents brain metastases formation in lung adenocarcinoma

Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., Srock, S., Perez-Moreno, P., Thorsen, F., Von Baumgarten, L., Preusser, M., Wick, W. & Winkler, F., Apr 1 2016, In : Molecular Cancer Therapeutics. 15, 4, p. 702-710 9 p.

Research output: Contribution to journalArticle

Neoplasm Metastasis
Brain
Vascular Endothelial Growth Factor A
Adenocarcinoma of lung
Bevacizumab
6 Citations (Scopus)

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D. G., Piacentini, F., Ambroggi, M., Cagossi, K., Gianni, L., Sarti, S., Bisagni, G., Ardizzoni, A., Conte, P. F. & Guarneri, V., Jul 5 2016, (Accepted/In press) In : Pharmacogenomics Journal.

Research output: Contribution to journalArticle

Immunoglobulin Fragments
Immunoglobulin G
Breast Neoplasms
Antibody-Dependent Cell Cytotoxicity
Drug Therapy

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., Cagossi, K., Gianni, L., Sarti, S., Bisagni, G., Ardizzoni, A., Conte, P. & Guarneri, V., Jul 5 2016, (Accepted/In press) In : Pharmacogenomics Journal.

Research output: Contribution to journalArticle

Immunoglobulin Fragments
Immunoglobulin G
Breast Neoplasms
Antibody-Dependent Cell Cytotoxicity
Drug Therapy

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., Cagossi, K., Gianni, L., Sarti, S., Bisagni, G., Ardizzoni, A., Conte, P. & Guarneri, V., Jul 5 2016, (Accepted/In press) In : Pharmacogenomics Journal.

Research output: Contribution to journalArticle

Immunoglobulin Fragments
Immunoglobulin G
Breast Neoplasms
Antibody-Dependent Cell Cytotoxicity
Drug Therapy

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., Cagossi, K., Gianni, L., Sarti, S., Bisagni, G., Ardizzoni, A., Conte, P. & Guarneri, V., Oct 2016, In : Pharmacogenomics Journal. 16, 5, p. 472-7 6 p.

Research output: Contribution to journalArticle

Immunoglobulin Fragments
Immunoglobulin G
Breast Neoplasms
Antibody-Dependent Cell Cytotoxicity
Drug Therapy
12 Citations (Scopus)
gemcitabine
Cisplatin
Adenocarcinoma
Hand-Foot Syndrome
Febrile Neutropenia

Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer

Callari, M., Cappelletti, V. G., D'Aiuto, F., Musella, V., Lembo, A., Petel, F., Karn, T., Iwamoto, T., Provero, P., Daidone, M. G., Gianni, L. & Bianchini, G., Jan 15 2016, In : Clinical Cancer Research. 22, 2, p. 337-345 9 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
Recurrence
Drug Therapy
Neoplasm Metastasis
15 Citations (Scopus)

Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer

Callari, M., Cappelletti, V., D'Aiuto, F., Musella, V., Lembo, A., Petel, F., Karn, T., Iwamoto, T., Provero, P., Daidone, M. G., Gianni, L. & Bianchini, G., Jan 15 2016, In : Clinical Cancer Research. 22, 2, p. 337-345 9 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms
Recurrence
Drug Therapy
Neoplasm Metastasis
1 Citation (Scopus)

The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine

Curigliano, G., Valagussa, P., Veronesi, U. & Gianni, L., Jan 1 2016, In : Annals of Oncology. 27, 1, p. 6-8 3 p.

Research output: Contribution to journalArticle

The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine

Curigliano, G., Valagussa, P., Veronesi, U. & Gianni, L., Jan 1 2016, In : Annals of Oncology. 27, 1, p. 6-8 3 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

Metzger-Filho, O., de Azambuja, E., Procter, M., Krieguer, M., Smith, I., Baselga, J., Cameron, D., Untch, M., Jackisch, C., Bell, R., Gianni, L., Goldhirsch, A., Piccart, M. & Gelber, R. D., Jan 1 2016, In : Breast Cancer Research and Treatment. 155, 1, p. 127-132 6 p.

Research output: Contribution to journalArticle

Recurrence
Therapeutics
Survival
Trastuzumab
Research Personnel